



RXVET
PHARMACEUTICALS



Vetoryl®

Treatment for pituitary-dependent hyperadrenocorticism (PDH) and adrenal-dependent canine hyperadrenocorticism (ADH)

Vetoryl® is the only veterinary-licensed product in New Zealand for the treatment of canine Cushing's syndrome.

Cushing's syndrome or canine hyperadrenocorticism is thought to be the most common endocrine disorder in the dog. The clinical signs arise due to an excess of circulating glucocorticoids, in particular cortisol, which is produced in the adrenal cortex.

Vetoryl® contains trilostane which reversibly reduces the production of cortisol by the adrenal glands. Clinical signs of Cushing's, such as lethargy, polydipsia, polyuria and polyphagia will improve usually within two weeks. Other signs such as pot belly and alopecia improve in 3-6 months.

ACVM Registration No's: A010903, A010935, A010936 and A010937

Product Features

- Fully reversible
- Can significantly improve quality of life
- Flexible and accurate dosing (available in four strengths, 10, 30, 60 and 120mg capsules)
- Licensed for long term administration

What dose to use?

- Initial dosage is approximately 2 mg/kg body weight given daily with breakfast for easy absorption
- Treatment should be monitored at 10 days, 4 weeks and 12 weeks and thereafter every 3 months.

For more information please contact your Veterinary Account Manager or RXVET Technical Support Line on 0800 4 RXVET (79838)

RXVET Limited | 0800 4 RXVET | info@rxvet.co.nz | www.rxvet.co.nz